Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 4,393 GBp
Change Today +8.00 / 0.18%
Volume 872.2K
As of 9:34 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZN) Snapshot

Open
4,388 GBp
Previous Close
4,385 GBp
Day High
4,428 GBp
Day Low
4,363 GBp
52 Week High
04/23/15 - 4,906 GBp
52 Week Low
06/30/15 - 4,019 GBp
Market Cap
55.5B
Average Volume 10 Days
2.3M
EPS TTM
0.94 GBp
Shares Outstanding
1.3B
EX-Date
08/13/15
P/E TM
73.1x
Dividend
3.14 GBp
Dividend Yield
4.45%
Current Stock Chart for ASTRAZENECA PLC (AZN)

astrazeneca plc (AZN) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. In addition, it engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Celgene Corporation, Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., and Pharmacyclics Inc. and Janssen Research & Development, LLC., as well as a strategic collaboration with Isis Pharmaceuticals, Inc. to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc (AZN) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc (AZN) Key Developments

AstraZeneca and Isis Pharmaceuticals, Inc. to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases

Isis Pharmaceuticals, Inc. and AstraZeneca announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca's strategic approach in these therapeutic areas using novel RNA-targeted treatments. It also enables Isis Pharmaceuticals to extend use of its antisense technology to diseases of the kidney. Antisense drugs are short, chemically modified, single-stranded nucleic acids (antisense oligonucleotides) that have the ability to target any gene product of interest. They offer new opportunities for therapeutic intervention because they act inside the cell to influence protein production by targeting RNA to either prevent the production of disease-causing proteins, increase the production of proteins deficient in disease, or target toxic RNAs that are unable to generate proteins. AstraZeneca will pay an upfront fee of $65 million to Isis Pharmaceuticals plus development and regulatory milestones for each program that AstraZeneca advances to clinical development. Isis Pharmaceuticals is also eligible to earn tiered double-digit royalties on annual net sales for each program. This transaction is subject to clearances under the Hart-Scott Rodino Antitrust Improvements Act.

Charles River Laboratories International Renews Strategic Partnership Agreement with AstraZeneca

Charles River Laboratories International reported the extension of its strategic drug development partnership with AstraZeneca. Under the agreement, Charles River Laboratories International has extended its initial three-year partnership with AstraZeneca for an additional five-year period. With extension into 2020, Charles River retains its position as AstraZeneca's preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).

AstraZeneca PLC Board Recommends First Interim Dividend for 2015, Payable on 14 September 14, 2015; Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Full Year of 2015

AstraZeneca PLC Board recommended an unchanged first interim dividend of $0.90. The record date for the first interim dividend for 2015, payable on September 14, 2015, will be August 14, 2015. Ordinary Shares listed in London and Stockholm will trade ex-dividend from August 13, 2015. American Depositary Shares listed in New York will trade ex-dividend from August 12, 2015. The company announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the second quarter, on reported basis, revenue was $6,307 million against $6,762 million a year ago. Operating profit was $923 million against $1,109 million a year ago. Profit before tax was $658 million against $866 million a year ago. Profit for the period was $696 million against $797 million a year ago. Profit attributable to the owners of the parent was $697 million against $796 million a year ago. Earnings per $0.25 ordinary share were $0.55 against $0.63 per basic and diluted share a year ago. On core basis, operating profit was $1,813 million against $2,031 million for the same period in the last year. Profit before tax was $1,679 million against $1,890 million for the same period in the last year. Profit after tax was $1,520 million against $1,643 million for the same period in the last year. Net profit was $1,520 million against $1,642 million for the same period in the last year. Earnings per share were $1.21 against $1.30 for the same period in the last year. For the six months, on reported basis, revenue was $12,364 million against $13,222 million for the same period in the last year. Operating profit was $1,856 million against $1,945 million for the same period in the last year. Profit before tax was $1,336 million against $1,504 million for the same period in the last year. Profit for the period was $1,248 million against $1,303 million for the same period in the last year. Profit attributable to owners of the parent was $1,247 million against $1,300 million for the same period in the last year. Diluted earnings per $0.25 Ordinary Share was $0.99 against $1.03 for the same period in the last year. Net cash inflow from operating activities was $1,008 million against $3,266 million for the same period in the last year. Purchase of property, plant and equipment was $497 million against $378 million for the same period in the last year. Purchase of intangible assets was $1,222 million against $1,490 million for the same period in the last year. Net debt as at June 30, 2015 was $5,994 million against $2,500 million a year ago. On core basis, operating profit was $3,618 million against $3,983 million for the same period in the last year. Profit before tax was $3,361 million against $3,716 million for the same period in the last year. Profit attributable to owners of the parent was $2,888 million against $3,113 million for the same period in the last year. Earnings per share were $2.29 against $2.47 for the same period in the last year. The company revised its total revenue guidance at CER from that provided on April 24, 2015. Total revenue in the full year is now expected to decline by low single-digit percent versus the prior guidance of a mid single-digit decline. Core EPS guidance at CER for the year is unchanged and Core EPS is expected to increase by low single-digit percent, reflecting the continued accelerated investment in R&D.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:LN 4,394.50 GBp +9.50

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $152.62 USD +2.22
Abbott Laboratories $50.97 USD +0.46
Biogen Inc $337.00 USD +6.62
Eli Lilly & Co $84.17 USD +0.12
Valeant Pharmaceuticals International Inc C$342.53 CAD +0.08
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
Price/Earnings 72.6x
Price/Sales 3.4x
Price/Book 4.7x
Price/Cash Flow 72.5x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.